Evidence map›Paper›PMID 36317894›Full record

ArticlemSphere2022

Leah V Goulding, Eleonóra Kiss, Robert Vrancken, Nesya Goris, Min Luo, Elisabetta Groaz, Piet Herdewijn, Linda Dixon

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Leah V GouldingThe Pirbright Institute, Pirbright, Woking, United Kingdom.ORCID 0000-0002-6371-8840
Eleonóra KissViroVet NV, Leuven, Belgium.
Robert VranckenViroVet NV, Leuven, Belgium.
Nesya GorisViroVet NV, Leuven, Belgium.
Min LuoKU Leuven, Rega Institute for Medical Research, Medicinal Chemistry, Leuven, Belgium.
Elisabetta GroazKU Leuven, Rega Institute for Medical Research, Medicinal Chemistry, Leuven, Belgium.
Piet HerdewijnKU Leuven, Rega Institute for Medical Research, Medicinal Chemistry, Leuven, Belgium.
Linda DixonThe Pirbright Institute, Pirbright, Woking, United Kingdom.ORCID 0000-0003-3845-3016
Rega Institute for Medical Research · BEThe Pirbright Institute · GB

Funding

Biotechnology and Biological Sciences Research Council BBS0152561Biotechnology and Biological Sciences Research Council BBS/E/I/00007037Biotechnology and Biological Sciences Research Council BBS/E/I/00007039
6 · The paper itself

Abstract

African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease with case fatality rates approaching 100% in domestic pigs. ASFV is responsible for substantial economic losses, but despite ongoing efforts, no vaccine or antiviral agent is currently available. Attempts to control the spread of ASFV are dependent on early detection, adherence to biosecurity measures, and culling of infected herds. However, an effective antiviral agent may be used in lieu of or in conjunction with a vaccine to effectively curb ASFV outbreaks. The dose-dependent antiviral activities of two amidate prodrugs (compounds 1a and 1b) of

Indexed as

African Swine Fever VirusProdrugsAnimalsAntiviral AgentsGenotypeNucleosidesNucleotidesSus scrofaSwineAntiviral AgentsNucleosidesNucleotidesProdrugsAfrican swine fever virusantiviral agentsDNA virusveterinary pathogens

Identifiers

PMID36317894
PMCPMC9769911
OpenAlexW4307841795

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.